longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

INNOCARE

09969

14.2901.52% ( -0.220 )
Delay Closed: Sep 25, 16:08:00
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 23.87, above the reasonable range, cheaper than 13.3% of the time in the past 5 years, and the industry ranks 14/78, the industry Median -5.50.

23.87xP/E
HK$14.29Stock price
HK$0.60Earnings per share
23.87xP/E
Stock priceHK$14.29Earnings per shareHK$0.60

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-19.12x
Typical range
-91.15x–-10.47x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0161322483644

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
09969HKINNOCARE
23.87x44.31%HK$25.25B
02162HKKEYMED BIO-B
25.14x275.88%HK$22.39B
02142HKHBM HOLDINGS-B
18.08x17.55%HK$11.98B
02157HKLEPU BIO
24.08x127.54%HK$6.85B
06826HKHAOHAI BIOTEC
20.61x128.24%HK$3.62B
02181HKMABPHARM-B
21.34x--HK$2.10B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.